Novel mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their efficacy in clinical trials, data on mRNA vaccine-induced immune responses are mostly limited to serological analyses. Here, we interrogated antibody and antigen-specific memory B cells over time in 33 SARS-CoV-2 naïve and 11 SARS-CoV-2 recovered subjects. SARS-CoV-2 naïve individuals required both vaccine doses for optimal increases in antibodies, particularly for neutralizing titers against the B.1.351 variant. Memory B cells specific for full-length spike protein and the spike receptor binding domain (RBD) were also efficiently primed by mRNA vaccination and detectable in all SARS-CoV-2 naive subjects after the second vaccine dose, though the memory B cell response declined slightly with age. In SARS-CoV-2 recovered individuals, antibody and memory B cell responses were significantly boosted after the first vaccine dose; however, there was no increase in circulating antibodies, neutralizing titers, or antigen-specific memory B cells after the second dose. This robust boosting after the first vaccine dose strongly correlated with levels of pre-existing memory B cells in recovered individuals, identifying a key role for memory B cells in mounting recall responses to SARS-CoV-2 antigens. Together, our data demonstrated robust serological and cellular priming by mRNA vaccines and revealed distinct responses based on prior SARS-CoV-2 exposure, whereby COVID-19 recovered subjects may only require a single vaccine dose to achieve peak antibody and memory B cell responses. These findings also highlight the utility of defining cellular responses in addition to serologies and may inform SARS-CoV-2 vaccine distribution in a resource-limited setting. Key differences in both antibody and memory B cell responses to mRNA vaccination were identified based on prior SARS-CoV-2 exposure.
【초록키워드】 COVID-19, antibodies, SARS-CoV-2, mRNA vaccination, Efficacy, Vaccine, serology, antibody, mRNA vaccine, B.1.351, B cells, memory B cells, clinical trials, SARS-CoV-2 vaccine, Spike protein, Receptor binding domain, mRNA vaccines, memory, Antigen, vaccine dose, RBD, mRNA, immune responses, response, age, recall, novel, distribution, utility, serological, memory B cell, Emergency use, SARS-CoV-2 antigens, Neutralizing titer, cellular response, cellular, dose, titers, Cellular responses, Spike receptor binding domain, circulating antibodies, subject, B.1.351 variant, second dose, no increase, naïve, priming, neutralizing titers, vaccine-induced immune response, full-length spike protein, antigen-specific memory B cells, single vaccine, responses, Cell, memory B, highlight, robust, significantly, addition, detectable, required, subjects, demonstrated, correlated, individuals, analyses, declined, increases in, naïve individual, 【제목키워드】 SARS-CoV-2, response, individual, Cell, memory B,